studies

MIBC - NA - PDL1 positive, immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias RFS/DFSdetailed resultsCheckMate 274 (PDL1>1%), 2017 0.55 [0.39; 0.78] 0.55[0.39; 0.78]CheckMate 274 (PDL1>1%), 201710%282NAnot evaluable DMFSdetailed resultsCheckMate 274 (PDL1>1%), 2017 0.61 [0.42; 0.89] 0.61[0.42; 0.89]CheckMate 274 (PDL1>1%), 201710%282NAnot evaluable events or deaths (EFS)detailed resultsCheckMate 274 (PDL1>1%), 2017 0.55 [0.35; 0.86] 0.55[0.35; 0.86]CheckMate 274 (PDL1>1%), 201710%282NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-13 07:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 253 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons